

Puneet Bhargava, MD

Associate Professor University of Washington



ACKNOWLEDGEMENTS William H. Bush, Jr., MD, FACR

Clinical Professor of Radiology University of Washington Medical Center Seattle, WA







 Neuroblastoma 	Wilms Tumor
 Calcification > 85% 	 Calcification=10%
 Encases vessels 	 Displaces vessels
 Crosses midline 	• Doesn' t usually cross
 Spinal canal extension 	 No extension to spinal canal
Metastases:	Metastases:
 bone common 	 lungs common
 lungs rare 	 bone rare

























Case: History of non small cell lung carcinoma



Rt Precontrast = - 10 HU

Lt Precontrast = 20 HU

Postcontrast = 120 HU

Washout = 50HU

Bilateral adrenal adenomas, lipid rich on right, lipid poor on left

TechniqueInjection $150 \text{ ml contrast at 2 ml/sec}$ Initial Enhanced attenuationmeasured at 5 secDelayed attenuationmeasured at 15 minutesDelayed attenuationmeasured at 15 minutesMeasureROI at least 1/2 size of massSensitivitySpecificityLikelihood ratio + testLikelihood ratio + test% Relative Washout (ade-nomas > 40%)82 (59-96)92 (79-98)% Enhancement Washout (adenomas > 60%)86 (65-98)92 (79-98)11 (4-34)n = 166 patients (adenoma 127, nonadenoma 39) (from Cacili et al)*								
TechniqueInjection150 ml contrast at 2 ml/secInitial Enhanced attenuationmeasured at 60 secDelayed attenuationmeasured at 12 minutesMeasureROI at least 1/2 size of massMeasureROI at least 1/2 size of massSensitivitySpecificitySensitivitySpecificity% Relative Washout (adenomas > 40%)82 (59-96)92 (79-98)11 (4-32)0.2 (0.08-0.48)n = 166 patients (adenomas >92 (79-98)n = 166 patients (adenomas >11 (4-34)n = 166 patients (adenomas >								
Injection150 ml contrast at 2 ml/secInitial Enhanced attenuationmeasured at 5 secDelayed attenuationmeasured at 15 minutesMeasureROI at least 12 size of massKensitiveSpecificitySensitivitySpecificityLikelihood ratio + testLikelihood ratio + test% Relative Washout (ade-nomas > 40%)S2 (59-96)% Enhancement Washout (ade-nomas > 60%)S6 (65-98)n = 166 patients (ade-nomation = n = 167 patients (ade-nomation = 167 patients (ade-nomatio	Technique							
Initial Enhanced attenuationmeasured at 6 secDelayed attenuationmeasured at 15 minutesMeasureROI at least 12 size of massMeasureSensitivitySensitivitySpecificityLikelihood ratio + testLikelihood ratio + test% Relative Washout (ade-nomas > 40%)82 (59-96)% Enhancement Washout (ade-nomas > 60%)92 (79-98)n = 166 patients (ade-nomation = 127, not enter 127, not e	Injection	150 ml contrast at 2 ml/sec						
Delayed attenuation Measuremeasured at 15 minutes ROI at least 1/2 size of massLikelihood ratio + 	Initial Enhanced attenuation	measured at 60 sec						
Measure ROI at least 1/2 size of mass Measure Solar teast 1/2 size of mass Sensitive Sensitive Sensitive Specificity Kelative Washout (ade-nomas > 40%) S2 (59-96) 92 (79-98) Kenhancement Washout (adenomas > 60%) Sensitive adenomas > 86 (65-98) 92 (79-98) I (4-32) O.15 (0.05-1.4) I = 166 patients (adenoma = 127, max-adenoma = 10) Sensitive adenoma = 100	Delayed attenuation	measured at 15 minutes						
SensitivitySpecificityLikelihood ratio + testLikelihood ratio + test% Relative Washout (adenomas > 40%)82 (59-96)92 (79-98)11 (4-32)0.2 (0.08-0.48)% Enhancement Washout (adenomas > 	Measure	ROI at least 1/2 size of mass						
% Relative Washout (adenomas > 40%) 82 (59-96) 92 (79-98) 11 (4-32) 0.2 (0.08-0.48) % Enhancement Washout (adenomas > 60%) 86 (65-98) 92 (79-98) 11 (4-34) 0.15 (0.05-1.4) n = 166 patients (adenoma 127, nonadenoma 39) (from Caoili et al)*			Sensitivity	Specificity	Likelihood ratio + test	Likelihood ratio - test		
% Enhancement Washout (adenomas > 86 (65-98) 92 (79-98) 11 (4-34) 0.15 (0.05-1.4) 60%) n = 166 patients (adenoma 127, nonadenoma 39) (from <u>Caoili et al</u>)*	% Relative Washout (adenomas > 40%)		82 (59-96)	92 (79-98)	11 (4-32)	0.2 (0.08-0.48)		
n = 166 patients (adenoma 127, nonadenoma 39) (from <u>Caoili et al</u>)*	% Enhancement Washout (adenomas > 60%)		86 (65-98)	92 (79-98)	11 (4-34)	0.15 (0.05-1.4)		
	n = 166 patients (adenoma 127, nonadenoma 39) (from <u>Caoili et al</u>)*							















Pheochromocytoma

- Composed of chromaffin cells
- Malignant 10 to 13%
- Extra-adrenal 10%
 - Paragangliomas: base of brain to epididymis, usually sympathetic chain in retroperitoneum
- Diagnosis is by assay of catecholamines and their
 - metabolites in blood or urine.
- Syndromes
 - MEN type 2
 - Von-Hippel Lindau disease
 - Neurofibromatosis
 - Carney's traid



Enhancing mass in the right adrenal gland (arrow). This was a pheochromocytoma.

Radin DR, Ralls PW, Boswell WD Jr, Colletti PM, Lapin SA, Halls JM (1986) Phaeochromocytoma detection by unenhanced CT. PJR 146: 741–744 van Heerden JA, Sheps SG, Hamberger B, Sheedy PF, Poston JG, ReMine WH (1982) Pheochromocytoma: current status and changing trends. Surgery 91: 367–373

Pheochromocytoma

- Rounded or oval masses of similar density to liver on noncontrast-enhanced scans.
- Central necrosis is frequent
- enhance markedly after injection of intravenous contrast medium



Axial (a) non-contrast and (b) post-contrast images showing an enhancing mass in the right adrenal gland. Central cystic areas may be due to necrosis. Coronal (c) reformat shows the suprarenal location of the mass.

Velchik MS, Alavi A, Kressel HY, Engelman K (1989) Localization of phaeochromocytomas: mIBG, CTand MRI correlation. J Nucl Med 30: 328–336 Quint LE, Glazer GM, Francis IR, Shapiro B, Chenevert TC (1987) Phaeochromocytoma and paraganglioma: comparison of MR imaging with CT and 1311 mIBG scintigraphy. Radiology 165: 89–93

Pheochromocytoma

- MRI
 - Hypointense on T1-weighted images and markedly hyperintense on T2-weighted images
 - 35% atypical signal intensity on T2-weighted images
 - Enhance markedly following injection



Right adrenal Pheochromocytoma: T2 coronal (a) and axial (b) image showing a isointense mass superior to the kidney with small cystic areas in it. Out of phase (c), Precontrast (d), and post contrast T1(e) images show a mildly enhancing mass.

Pheochromocytoma

• NM -

- Iodine 131

metaiodobenzylguanidine (MIBG) or indium-labelled penetreotide (Octreoscan), particularly helpful for extraadrenal lesions



Patient with MEN syndrome with a Pheochormocytoma and medullary thyroid CA. Focus of increased uptake in the left adrenal gland consistent with a pheochromocytoma and another focus of increased uptake in the right inferior thyroid which was shown to be consistent with a solid lesion on US. This was a medullary thyroid carcinoma. MRI confirmed the pheochromocytoma in the left adrenal gland (red arrow)





























































90 % newborns & infants; 80 % benign



Sacral Teratoma